作者
Luis Ortega-Paz, Mattia Galli, Davide Capodanno, Francesco Franchi, Fabiana Rollini, Behnood Bikdeli, Roxana Mehran, Gilles Montalescot, C Michael Gibson, Renato D Lopes, Felicita Andreotti, Dominick J Angiolillo
发表日期
2022/11
来源
European Heart Journal-Cardiovascular Pharmacotherapy
卷号
8
期号
7
页码范围
677-686
出版商
Oxford University Press
简介
Background
The clinical impact of different prophylactic anticoagulation regimens among hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We pooled evidence from available randomized controlled trials (RCTs) to provide insights on this topic.
Methods and results
We searched for RCTs comparing treatment with an escalated-dose (intermediate-dose or therapeutic-dose) vs. a standard-dose prophylactic anticoagulation regimen in critically and non-critically ill COVID-19 patients requiring hospitalization and without a formal indication for anticoagulation. The primary efficacy endpoint was all-cause death, and the primary safety endpoint was major bleeding. Seven RCTs were identified, including 5154 patients followed on an average of 33 days. Compared to standard-dose prophylactic anticoagulation, escalated-dose prophylactic …
学术搜索中的文章
L Ortega-Paz, M Galli, D Capodanno, F Franchi… - European Heart Journal-Cardiovascular …, 2022